Paul Emery and John Fitton present the case of a patient who has responded to treatment with the JAK inhibitor tofacitinib as her sixth-line targeted therapy for biologic-refractory rheumatoid arthritis.
Laura Coates talks to medwireNews about the latest ACR/NPF guidelines for managing psoriatic arthritis, discussing the evidence supporting the recommendations and how they compare with others.
Filgotinib, given in combination with methotrexate, may be a promising treatment option for methotrexate-naïve patients with moderate-to-severe rheumatoid arthritis, indicate findings from the FINCH 3 trial.
Analysis of the EQUATOR trial has shown that patients treated with the Janus kinase inhibitor filgotinib for active psoriatic arthritis generally achieve a quick response that remains stable over time.
Approximately half of the 21 patients with juvenile idiopathic arthritis-associated uveitis in the APTITUDE trial experienced an improvement in uveitis assessment with 12 weeks of tocilizumab treatment.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.
